Pilot Study on Evaluating the Geroprotective Effect of Metformin
A Phase II Exploratory Clinical Study Investigating the Geroprotective Effect of Metformin in Middle-aged and Elderly People
Xuanwu Hospital, Beijing
130 participants
Jun 30, 2024
INTERVENTIONAL
Conditions
Summary
The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.
Eligibility
Inclusion Criteria5
- Male
- Age 55-65; 18-28;
- Able to understand and execute instructions;
- After reading the consent form, be able to answer questions about the study and demonstrate understanding of the protocol;
- Be able to participate in regular follow-up visits.
Exclusion Criteria8
- Severe chronic or acute disease: cancer, clinically significant congestive heart failure, chronic obstructive pulmonary disease (COPD), previous or new-onset diabetes, inflammatory state, serum creatinine >1.5 mg/dl , active liver disease, History of metabolic acidosis, poorly controlled hypertension, epilepsy, recent (within 3 months) cardiovascular events (MI, PTCA, CABG, stroke), severe renal insufficiency, inflammatory bowel disease, persistent glucocorticoids Treatment; neurological diseases such as dementia, AD, PD, etc.; infectious diseases such as HIV, hepatitis, tuberculosis, etc.; severe autoimmune diseases;
- BMI<18.5 or BMI>30;
- Persistent alcohol or drug abuse;
- Treatment with drugs known to affect glucose metabolism (other diabetes drugs, systemic glucocorticoids, niacin);
- Hypersensitivity to metformin or any component of the preparation;
- Have taken metformin, low-dose aspirin, acarbose, vitamin C in the recent (3 months);
- Unable to provide informed consent;
- Other circumstances in which the researcher believes that the physical factors of the participants may adversely affect the research process or results.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Extended release oral tablets, 1000 mg/day, single dose
Oral tablets, 1000 mg/day, single dose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06459310